trending Market Intelligence /marketintelligence/en/news-insights/trending/SCAG7NFlpnAq_6r3u976vg2 content esgSubNav
In This List

EMA accepts The Medicines Co.'s application for urinary tract infection drug

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


EMA accepts The Medicines Co.'s application for urinary tract infection drug

The European Medicines Agency acknowledged receipt of The Medicines Company's application for Vabomere to treat complicated urinary tract infections.

The application is backed by data from phase 3 trial. Vabomere was previously known as Carbavance.